Search
Lee's Pharmaceutical's Anti-PD-L1 Monoclonal Antibody Receives Approval for Small Cell Lung Cancer Therapy
1 week ago /
Read about 0 minute
Author：小编
Socazolimab, a fully human PD-L1 monoclonal antibody that maintains a complete Fc region, leverages antibody-dependent cellular cytotoxicity to enhance the tumoricidal activity of immune cells. This groundbreaking drug has been granted approval for use as a first-line therapy in combination with chemotherapy for patients with extensive-stage small cell lung cancer. Additionally, it is indicated for the treatment of recurrent or metastatic cervical cancer. By effectively blocking the PD-1/PD-L1 signaling pathway, Socazolimab empowers the immune system to target and destroy tumor cells, thereby offering patients a novel and promising treatment option.
-
C114 Communication Network -
Communication Home
7 X 24 Track global technological trends
